Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUOPANC phase II fluorescence imaging study in pancreatic and extrahepatic bile duct tumors
2019-004217-14Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cRGD-ZW800-1 in pancreatic cancer (PC) and cholangiocarcinoma (CCA), sponsored by Leiden University Medical Center. Primary endpoint: Primary tumor visualization. Started Aug 2022; status: completed.
02
Drugs
cRGD-ZW800-1
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2019-004217-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004217-14.